Preclinical evaluation of MEDI0641, a pyrrolobenzodiazepine-conjugated antibody–drug conjugate targeting 5T4

Molecular Cancer Therapeutics

Volumn 16, Issue 8, 2017, Pages 1576-1587

  Harper, Jay ^a   Lloyd, Christopher ^b   Dimasi, Nazzareno ^a   Toader, Dorin ^a   Marwood, Rose ^b   Lewis, Leeanne ^b   Bannister, David ^b   Jovanovic, Jelena ^b   Fleming, Ryan ^a   D'Hooge, Francois ^c   Mao, Shenlan ^a   Marrero, Allison M ^a   Korade, Martin ^a   Strout, Patrick ^a   Xu, Linda ^a   Chen, Cui ^a   Wetzel, Leslie ^a   Breen, Shannon ^a   Van Vlerken Ysla, Lilian ^a   Jalla, Sanjoo ^a   Rebelatto, Marlon ^a   Zhong, Haihong ^a   Hurt, Elaine M ^a   Hinrichs, Mary Jane ^a   Huang, Keven ^a   Howard, Philip W ^c   Tice, David A ^a   Hollingsworth, Robert E ^a   Herbst, Ronald ^a   Kamal, Adeela ^a,d   more..

^a MEDIMMUNE   (United States)

^b MEDIMMUNE LTD   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d Ferring Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5T4 PROTEIN; ANTIBODY CONJUGATE; BENZODIAZEPINE DERIVATIVE; CASPASE 3; CASPASE 7; CYSTEINE; DIMER; MEDI 0641; PROTEIN; TUBULYSIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PYRROLE DERIVATIVE; PYRROLO(2,1-C)(1,4)BENZODIAZEPINE; TUBULIN MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW SUPPRESSION; CANCER INHIBITION; CELL DEATH; COMPARATIVE STUDY; CONJUGATION; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY ASSAY; DILUTION; DNA CROSS LINKING; DRUG CONJUGATION; DRUG CYTOTOXICITY; EFFECTOR CELL; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; MICROARRAY ANALYSIS; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; SINGLE DRUG DOSE; TUMOR REGRESSION; TUMOR VOLUME; WEIGHT GAIN; WEIGHT REDUCTION; ANIMAL; CANCER STEM CELL; DRUG EFFECT; DRUG SCREENING; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; CELL LINE, TUMOR; HUMANS; IMMUNOCONJUGATES; MALE; MICE; MICE, NUDE; NEOPLASTIC STEM CELLS; PYRROLES; RATS, SPRAGUE-DAWLEY; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85027185733     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0825     Document Type: Article

References (50)

1. Polakis P. Antibody drug conjugates for cancer therapy. Pharmacol Rev 2016;68:3–19.
2. De Goeij BECG, Lambert JM. New developments for antibody-drug conjugate-based therapeutic approaches. Curr Opin Immunol 2016;40:14–23.
3. Diamentis N, Banerji U. Antibody-drug conjugates – an emerging class of cancer treatment. Br J Cancer 2016;114:362–7.
4. Hole N, Stern PL. A 72kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer 1990;57:239–46.
5. Hole N, Stern PL. Isolation and characterization of 5T4, a tumor-associated antigen. Int J Cancer 1990;45:179–84.
6. Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL. Immunohistological distribution of 5T4 antigen in normal and malignant tissue. Br J Cancer 1990;61:89–95.
7. Starzynska T, Rahi V, Stern PL. The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer 1992;66:867–69.
8. Wrigley E, McGown AT, Rennison J, Swindell R, Crowther D, Starzynska T, et al. 5T4 oncofetal antigen expression in ovarian cancer. Int J Gynecol Cancer 1995;5:269–74.
9. Griffiths RW, Gillham DE, Dangoor A, Ramani V, Clarke NW, Stern PL, et al. Expression of the 5T4 oncofetal antigen in renal cell carcinoma: a potential target tor T-cell-based immunotherapy. Br J Cancer 2005;93: 670–7.
10. Al-Taei S, Salimu J, Lester JF, Linnane S, Goonewardena M, Harrop R, et al. Overexpression and potential targeting of the oncofetal antigen 5T4 in malignant pleural mesothelioma. Lung Cancer 2012; 77:312–8.
11. Mulder WMC, Stern PL, Stukart MJ, de Windt E, Butzelaar RMJM, Meijer S, et al. Low intracellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients. Clin Cancer Res 1997;3:1923–30.
12. Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA, Stern PL. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer 1994;69:899–902.
13. Starzynska T, Wiechowska-Kozlowska A, Marlicz K, Bromley M, Roberts SA, Lawniczak M, et al. 5T4 oncofetal antigen in gastric carcinoma and its clinical significance. Eu J Gastroenterol Hepatol 1998;10:479–84.
14. Myers KA, Rahi-Saund V, Davison MD, Young JA, Cheater AJ, Stern PL. Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein. J Biol Chem 1994;269:9319–24
15. Southgate TD, McGinn OJ, Castro FV, Rutkowski AJ, Al-Muftah M, Marinov G, et al. CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells. PLoS One 2010;5:e9982.
16. Yoshihara S-i, Takahashi H, Tsuboi A. Molecular mechanisms regulating the dendritic development of newborn olfactory bulb interneur-ons in a sensory-experience-dependent manner. Front Neurosci 2016;9: Article 514.
17. Zhao Y, Malinauskas T, Harlos K, Jones EY. Structural insights into the inhibition of Wnt signaling by cancer antigen 5T4/Wnt-activated inhibitory factor 1. Structure 2014;22:612–20.
18. Awan A, Lucic MR, Shaw DM, Sheppard F, Westwater C, Lyons SA, et al. 5T4 interacts with TIP-2/GIPC, a PDZ protein, with implications for metastasis. Biochem Biophys Res Commun 2002;290:1030–6.
19. Carsberg CJ, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int J Cancer 1996;68:84–92.
20. Spencer HL, Eastham AM, Merry CLR, Southgate TD, Perez-Campo F, Soncin F, et al. E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells. Mol Biol Cell 2007;18:2838–51.
21. Damelin M, Geles KG, Follettie MT, Yuan P, Baxter M, Golas J, et al. Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells. Cancer Res 2011;71:4236–46.
22. Kerk SA, Finkel KA, Pearson AT, Warner K, Nor F, Zhang Z, et al. 5T4-targeted therapy ablates cancer stem cells and prevents recurrence of head and neck squamous cell carcinoma. Clin Cancer Res 2017;23: 2516–27.
23. Sapra P, Damelin M, DiJoseph J, Marquette K, Geles KG, Golas J, et al. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther 2013;12:38–47.
24. Shor B, Kahler J, Dougher M, Xu J, Mack M, Rosfjord E, et al. Enhanced antitumor activity of an anti-5T4 antibody-drug conjugate in combination with PI3K/mTOR inhibitors or taxanes. Clin Cancer Res 2015;22:383–94.
25. Shapiro GI, Vaishampayan UN, LoRusso P, Barton J, Hua S, Reich SD, et al. First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors. Invest New Drugs 2017;35:315–23.
26. Hartley J. The development of pyrrolobenzodiazepines as antitumor agents. Expert Opin Investig Drugs 2011;20:733–44.
27. Tiberghien AC, Levy J-N, Masterson LA, Patel NV, Adams LR, Corbett S, et al. Design and synthesis of tesirine, a clinical antibody–drug conjugate pyrrolobenzodiazepine dimer payload. ACS Med Chem Lett 2016; 7:983–7.
28. Toader D, Wang F, Gingipalli L, Vasbinder MM, Roth M, Mao S, et al. Structure-cytotoxicity relationships of analogs of N14-desacetocytubulysin H. J Med Chem 2016;59:10781–7.
29. Murphy AJ, Macdonald LE, Stevens S, Karow M, Dore AT, Pobursky K, et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc Natl Acad Sci U S A 2014;111:5153–8.
30. Douthwaite JA, Sridharan S, Huntington C, Hammersley J, Marwood R, Hakulinen JK, et al. Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1. MAbs 2015;7:152–66.
31. Dennis MS, Lowman HB. Phage selection strategies for improved affinity and specificity of proteins and peptides. In:Clackson T, Lowman HB, editors. Phage display, a practical approach. Oxford, United Kingdom: Oxford University Press; 2004. p. 61–84.
32. Thompson J, Pope T, Tung JS, Chan C, Hollis G, Mark G, et al. Affinity maturation of a high-affinity human monoclonal antibody against the third hypervariable loop of human immunodeficiency virus: use of phage display to improve affinity and broaden strain reactivity. J Mol Biol 1996:256:77–88.
33. Osbourn JK, Field A, Wilton J, Derbyshire E, Earnshaw JC, Jones PT, et al. Generation of a panel of related human scFV antibodies with high affinities for human CEA. Immunotechnology 1996;2:181–96.
34. Thompson P, Fleming R, Bezabeh B, Huang F, Mao S, Chen C, et al. Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and phar-macokinetics. J Control Release 2016;236:100–16.
35. Edelman GM, Cunningham BA, Gall WE, Gottlieb PD, Rutishauser U, Waxdal MJ. The covalent structure of an entire gamma G immunoglobulin molecule. Proc Natl Acad Sci U S A 1969;63:78–85.
36. Thornberry NA, Rano TA, Peterson EP, Rasper DM, Timkey T, Garcia-Calvo M, et al. A combinatorial approach defines specificities of members of the caspase family and granzyme B. Functional relationships established for key mediators of apoptosis. J Biol Chem 1997;272:17907–11.
37. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003;100:3983–8.
38. de Beça FF, Caetano P, Gerhard R, Alvarenga CA, Gomes M, Paredes J, et al. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J Clin Pathol 2013;66:187–91.
39. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB, Farrar WL. CD44þCD24 (-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 2008;98:756–65.
40. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. Significance of CD90þ cancer stem cells in human liver cancer. Cancer Cell 2008;13: 153–66.
41. Katsuno Y, Ehata S, Yashiro M, Yanagihara K, Hirakawa K, Miyazono K. CoordinatedexpressionofREG4andaldehydedehydrogenase1regulating tumourigenic capacity of diffuse-type gastric carcinoma-initiating cells is inhibited by TGF-b. J Pathol 2012;228:391–404.
42. Zhu J, He J, Liu Y, Simeone DM, Lubman DM. Identification of glycoprotein markers for pancreatic cancer CD24þCD44þ stem-like cells using nano-LC-MS/MS and tissue microarray. J Proteome Res 2012; 11:2272–81.
43. Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, et al. A potent anti-CD70 antibody–drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem 2013;24:1256–63.
44. Vidal SJ, Rodriquez-Bravo V, Galsky M, Cordon-Cardo C, Domingo-Domenech J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 2014;33:4451–63.
45. Scales SJ, Gupta N, Pacheco G, Firestein R, French DM, Koeppen H, et al. An antimesothelin-monomethyl auristatin e conjugate with potent antitumor activity in ovarian, pancreatic, and mesothelioma models. Mol Cancer Ther 2014;13:2630–40.
46. Breij EC, de Goeij BE, Verploegen S, Schuurhuis DH, Amirkhosravi A, Francis J, et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res 2014;74:1214–26.
47. Phillips GD, Li G, Dugger D, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody–cytotoxic drug conjugate. Cancer Res 2008;68: 9280–90.
48. Nguyen M, Miyakawa S, Kato J, Mori T, Arai T, Armanini M, et al. Preclinical efficacy and safety assessment of an antibody-drug conjugate targeting the c-RET proto-oncogene for breast carcinoma. Clin Cancer Res 2015;21: 5552–62.
49. Mang Y, Zhao Z, Zeng Z, Wu X, Li Z, Zhang L. Efficient elimination of CD103-expressing cells by anti-CD103 antibody drug conjugates in immu-nocompetent mice. Int Immunopharmacol 2015;24:119–27.
50. Boghaert ER, Sridharan L, Khandke KM, Armellino D, Ryan MG, Myers K, et al. The oncofetal protein, 5T4, is a suitable target for antibody-guided anticancer chemotherapy with calicheamicin. Int J Oncol 2008;32:221–34.